Herbert Virgin - 30 Nov 2021 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP, Research & CSO
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
30 Nov 2021
Net transactions value
-$727,059
Form type
4
Filing time
02 Dec 2021, 16:12:52 UTC
Previous filing
18 Nov 2021
Next filing
16 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $23,141 +15,125 +14% $1.53* 122,825 30 Nov 2021 Direct
transaction VIR Common Stock Sale $62,700 -1,375 -1.1% $45.60 121,450 30 Nov 2021 Direct F1
transaction VIR Common Stock Sale $687,500 -13,750 -11% $50.00 107,700 30 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -15,125 -6.2% $0.000000 230,505 30 Nov 2021 Common Stock 15,125 $1.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
F2 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.